$111 Million is the total value of Lynx1 Capital Management LP's 12 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BLU | Sell | BELLUS HEALTH INC NEW | $25,155,000 | -3.9% | 2,382,127 | -15.9% | 22.69% | +1.8% |
| ALPN | Buy | ALPINE IMMUNE SCIENCES INC | $22,006,000 | +34.2% | 3,056,420 | +58.6% | 19.85% | +42.1% |
| KNTE | KINNATE BIOPHARMA INC | $20,012,000 | -5.2% | 1,674,677 | 0.0% | 18.05% | +0.3% | |
| MRUS | Sell | MERUS N V | $12,280,000 | -45.8% | 613,071 | -38.8% | 11.08% | -42.6% |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $8,140,000 | +6.5% | 2,325,833 | -10.2% | 7.34% | +12.8% |
| AVTE | Buy | AEROVATE THERAPEUTICS INC | $4,583,000 | +53.1% | 276,447 | +44.3% | 4.13% | +62.1% |
| Buy | PARDES BIOSCIENCES INC | $4,210,000 | -37.1% | 2,275,732 | +4.4% | 3.80% | -33.4% | |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $4,042,000 | -32.9% | 3,515,140 | +9.1% | 3.65% | -29.0% |
| PASG | Buy | PASSAGE BIO INC | $3,441,000 | +245.8% | 2,752,422 | +553.1% | 3.10% | +266.0% |
| IMUX | Sell | IMMUNIC INC | $3,388,000 | -11.6% | 1,072,288 | -2.9% | 3.06% | -6.4% |
| THESEUS PHARMACEUTICALS INC | $2,928,000 | +4.9% | 504,862 | 0.0% | 2.64% | +11.1% | ||
| OTIC | Buy | OTONOMY INC | $682,000 | +1000.0% | 2,312,880 | +7609.6% | 0.62% | +1060.4% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MERUS N V | 8 | Q3 2023 | 21.9% |
| ALPINE IMMUNE SCIENCES INC | 8 | Q3 2023 | 20.2% |
| CYMABAY THERAPEUTICS INC | 8 | Q3 2023 | 10.0% |
| THESEUS PHARMACEUTICALS INC | 8 | Q3 2023 | 5.6% |
| PIERIS PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
| KINNATE BIOPHARMA INC | 7 | Q3 2023 | 18.0% |
| PARDES BIOSCIENCES INC | 7 | Q2 2023 | 11.0% |
| PASSAGE BIO INC | 7 | Q3 2023 | 4.0% |
| BELLUS HEALTH INC NEW | 6 | Q1 2023 | 22.7% |
| CABALETTA BIO INC | 4 | Q3 2023 | 22.6% |
View Lynx1 Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13G | 2024-04-01 |
| SC 13G | 2024-03-29 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Lynx1 Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.